MX2024007091A - Anticuerpos caninizados y felinizados contra el ngf humano. - Google Patents
Anticuerpos caninizados y felinizados contra el ngf humano.Info
- Publication number
- MX2024007091A MX2024007091A MX2024007091A MX2024007091A MX2024007091A MX 2024007091 A MX2024007091 A MX 2024007091A MX 2024007091 A MX2024007091 A MX 2024007091A MX 2024007091 A MX2024007091 A MX 2024007091A MX 2024007091 A MX2024007091 A MX 2024007091A
- Authority
- MX
- Mexico
- Prior art keywords
- caninized
- human ngf
- antibodies
- felinized antibodies
- felinized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290264P | 2021-12-16 | 2021-12-16 | |
| US202263327076P | 2022-04-04 | 2022-04-04 | |
| PCT/EP2022/086097 WO2023111157A1 (en) | 2021-12-16 | 2022-12-15 | Caninized and felinized antibodies to human ngf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007091A true MX2024007091A (es) | 2024-08-22 |
Family
ID=84888668
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007091A MX2024007091A (es) | 2021-12-16 | 2022-12-15 | Anticuerpos caninizados y felinizados contra el ngf humano. |
| MX2024007088A MX2024007088A (es) | 2021-12-16 | 2022-12-15 | Anticuerpos caninizados contra el ngf humano. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007088A MX2024007088A (es) | 2021-12-16 | 2022-12-15 | Anticuerpos caninizados contra el ngf humano. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20250340626A1 (https=) |
| EP (2) | EP4448568A1 (https=) |
| JP (2) | JP2025500805A (https=) |
| AU (2) | AU2022409611A1 (https=) |
| CA (2) | CA3240904A1 (https=) |
| MX (2) | MX2024007091A (https=) |
| WO (2) | WO2023111157A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208157A1 (en) | 2020-09-04 | 2023-07-12 | Elanco Us Inc. | Palatable formulations |
| FR3149894A1 (fr) | 2023-06-13 | 2024-12-20 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Grain fondu à base d’alumine |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| CA2975521A1 (en) | 2001-05-30 | 2002-12-05 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| AR045056A1 (es) | 2003-07-15 | 2005-10-12 | Amgen Inc | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf |
| MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| CA2875783C (en) * | 2012-06-06 | 2018-12-11 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
| CN106029697B (zh) | 2013-12-20 | 2021-06-04 | 英特维特国际股份有限公司 | 具有经修饰的ch2-ch3序列的犬抗体 |
| BR112020017701A2 (pt) * | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | Anticorpos anti-ngf e métodos dos mesmos |
-
2022
- 2022-12-15 CA CA3240904A patent/CA3240904A1/en active Pending
- 2022-12-15 MX MX2024007091A patent/MX2024007091A/es unknown
- 2022-12-15 CA CA3239613A patent/CA3239613A1/en active Pending
- 2022-12-15 JP JP2024534461A patent/JP2025500805A/ja active Pending
- 2022-12-15 EP EP22839650.3A patent/EP4448568A1/en active Pending
- 2022-12-15 WO PCT/EP2022/086097 patent/WO2023111157A1/en not_active Ceased
- 2022-12-15 EP EP22840576.7A patent/EP4448569A1/en active Pending
- 2022-12-15 AU AU2022409611A patent/AU2022409611A1/en active Pending
- 2022-12-15 US US18/720,582 patent/US20250340626A1/en active Pending
- 2022-12-15 AU AU2022410351A patent/AU2022410351A1/en active Pending
- 2022-12-15 JP JP2024534470A patent/JP2025500806A/ja active Pending
- 2022-12-15 WO PCT/EP2022/086091 patent/WO2023111153A1/en not_active Ceased
- 2022-12-15 US US18/720,586 patent/US20250346657A1/en active Pending
- 2022-12-15 MX MX2024007088A patent/MX2024007088A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3240904A1 (en) | 2023-06-22 |
| AU2022410351A1 (en) | 2024-05-30 |
| JP2025500805A (ja) | 2025-01-15 |
| EP4448569A1 (en) | 2024-10-23 |
| CA3239613A1 (en) | 2023-06-22 |
| US20250340626A1 (en) | 2025-11-06 |
| WO2023111157A1 (en) | 2023-06-22 |
| WO2023111153A1 (en) | 2023-06-22 |
| JP2025500806A (ja) | 2025-01-15 |
| US20250346657A1 (en) | 2025-11-13 |
| MX2024007088A (es) | 2024-08-22 |
| AU2022409611A1 (en) | 2024-07-04 |
| EP4448568A1 (en) | 2024-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012304A (es) | Anticuerpos anti-il31 para uso veterinario | |
| MX2024007091A (es) | Anticuerpos caninizados y felinizados contra el ngf humano. | |
| MX2021004313A (es) | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| MX2009006066A (es) | Tratamiento de cerdos con el antigeno pcv. | |
| PH12020551865A1 (en) | Anti-msr1 antibodies and methods of use thereof | |
| MX2022008341A (es) | Anticuerpos anti-ccr8 y usos de estos. | |
| MX2023001726A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| CR20210622A (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| MX353319B (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| MX2022015609A (es) | ANTICUERPOS ANTI-TGFß Y USOS TERAPÉUTICOS DE ESTOS. | |
| ECSP066526A (es) | Anticuerpos que se unen al receptor de interleuquina-4 | |
| MX2023000448A (es) | Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta. | |
| EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
| MX2023006832A (es) | Anticuerpos que se unen a receptores de linfocitos t gamma-delta. | |
| MX2024011444A (es) | Anticuerpos anti-npr1 y usos de los mismos. | |
| EA201370081A1 (ru) | Антитела к cd48 и их применение | |
| MX2022013147A (es) | Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario. | |
| BR112014031028A2 (pt) | Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista | |
| EA201071068A1 (ru) | Антитела к tyrp1 | |
| NZ757956A (en) | Il4/il13 receptor molecule for veterinary use | |
| BR112021018156A2 (pt) | Antagonistas de ngf para uso médico | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| PH12021552148A1 (en) | Cd3 binding molecules |